PARIS–(Business WIRE)–Feb 3, 2021–
TISSIUM, a privately-owned medtech corporation creating biomorphic programmable polymers for tissue reconstruction, announced now that it has additional to its management crew as it looks to speed up its partnership method and enhance its concentration on the U.S. current market.
As section of this work, the Firm has appointed Hunt Henrie as its Main Small business Officer and Seth Schulman as its Vice President of Worldwide Regulatory and Medical Affairs.
Throughout his considerable and assorted occupation, Mr. Henrie has invested three a long time as a worldwide chief in the finance industry, which include far more than 25 yrs in expenditure banking, non-public fairness and undertaking investing. As a end result, he has created large expertise driving approach, business enterprise growth and investments for worldwide medtech and daily life science businesses.
Most not long ago, Mr. Henrie served as Taking care of Director and World-wide Head of Medtech at Locust Walk, an unbiased strategic advisory, M&A, and funds marketplaces expense financial institution. He also held positions at Ferghana Associates and J.P. Morgan Chase, between other individuals. Mr. Henrie is a former member of the board of administrators at XShares and he advises a range of innovative medtech firms. He earned a bachelor’s diploma from Boston College in Worldwide Relations, a master’s degree from The Johns Hopkins University’s Paul H. Nitze College of Innovative Intercontinental Scientific tests, and he attended Stanford University’s Graduate Faculty of Organization Government Schooling Software.
Mr. Schulman has invested extra than 25 many years in regulatory affairs at health care product and biotech businesses throughout the U.S. Most just lately, Mr. Schulman served as Vice President, Regulatory Affairs at Penumbra Inc., a worldwide healthcare enterprise creating health-related units and revolutionary therapies. Prior to that, he held roles at Genzyme Biosurgery (now, Sanofi Genzyme), Medtronic Vascular, and Boston Scientific. He attained his bachelor’s degree in Biology from Tufts College.
“TISSIUM will benefit tremendously from the wisdom and business enterprise acumen that Hunt and Seth can provide for our corporation, particularly as we look to expand the business enterprise and meet our strategic goals. The addition of an field veteran such as Hunt to TISSIUM’s roster drastically enhances our ability to accomplish our target to be a chief in tissue reconstruction by means of partnerships with industry, setting up with our two packages in Cardiovascular and Hernia repair service,” reported Christophe Bancel, CEO of TISSIUM. “Additionally, the appointment of Seth delivers the needed Regulatory working experience to TISSIUM as we posture the firm to increase our platform of merchandise with numerous indications and go into a new section in Europe and primarily the U.S.”
Mr. Henrie said, “I am thrilled to be a part of the crew at this important time and aid Christophe’s management and distinctive vision for TISSIUM. The organization is innovating at a high stage and I am fired up to help the company’s mission to enable clients by bringing its proprietary platform of biomorphic programmable polymer-based mostly solutions to market.”
Mr. Schulman explained, “I am quite delighted to be part of TISSIUM during this time of development and acceleration. Throughout my occupation, I have been passionate about helping to create professional medical technologies that offer sizeable scientific gain to clients and medical professionals, advancing products by the regulatory method, and determining the best strategy for these technologies to attain sufferers. As I just take on this new function, I am thrilled to join the group in leading TISSIUM into this subsequent stage.”
TISSIUM is a privately-owned medtech organization based mostly in Paris, France that is committed to the speedy improvement and commercialization of a distinctive biopolymer system to address numerous unmet scientific desires.
The company’s system is centered on a proprietary polymer family members with one of a kind qualities including the capacity to conform to and integrate with encompassing tissue to allow tissue reconstruction. In addition, the polymer building blocks empower customization to match tissue-unique demands for various therapeutic parts. The corporation is establishing a portfolio of solutions for peripheral nerve, gastrointestinal, ENT and cardiovascular applications. The firm also develops shipping and delivery and activation gadgets for improved overall performance and usability of its family members of polymers.
TISSIUM’s technologies is based mostly on world-course analysis and mental property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-launched the business in 2013. For additional info, please check out: www.TISSIUM.com and @TISSIUMtech.
Brice Epry – Chief of Personnel
Twitter: @TISSIUMtechU.S.
Marketplace Key word: BIOTECHNOLOGY OTHER Wellbeing Well being PHARMACEUTICAL OTHER SCIENCE Clinical Units Investigate HOSPITALS Surgery SCIENCE Medical TRIALS
Copyright Organization Wire 2021.
PUB: 02/03/2021 08:00 AM/DISC: 02/03/2021 08:01 AM
Copyright Organization Wire 2021.
